The Mbale Clinical Research Institute (MCRI) remains committed to progressive research collaborations with Busitema University. In the last 7 years, we have learnt and grown together in research at Mbale Campus. If there is anything that an academician, research institute and University would be proud of, it is to make a humble contribution through asking key research questions whose answers directly advance the wellbeing of humanity and development. The MCRI and Busitema University research collaboration is just about that!
Mbale Clinical Research Institute Laboratory And Biobank Building.
A centre of excellence in evidence based clinical research, training and innovation,
To provide high quality evidence based clinical research and training for sustainable development
Integrity,Team work, Accuracy,
Mbale Clinical Research Institute (MCRI) advances Clinical Research in pursuit of a vision “Center for Excellence in Evidence based Clinical Research, Training and Innovation” within Uganda and internationally.
Senior Fellow: Professor Peter Olupot-Olupot, MB.Ch.B, MPH, PhD, SRF, FUNAS Title
Strengthening Malaria Epidemiological, Pathophysiological and Intervention Studies in Highly Endemic Eastern Uganda (MEPIE)
Scaling up of Capacity of Research Ethics Committees in Uganda (SCRECU)
The Uganda National Council of Science and Technology (UNCST), Busitema University and Mbale Regional Referral Hospital are in a consortium aimed at Scaling up of Capacity of Research Ethics Committees in Uganda (SCRECU).
Realizing Effectiveness Across Continents with Hydroxyurea (REACH) is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed Sudden Cardiac Arrest (SCA) between 12 months and 10 years.
The Transfusion and Treatment of severe Anaemia in African Children (TRACT) is a randomized controlled Trial. TRACT is evaluating three different ways to reduce short and longer-term mortality and morbidity following admission to hospital with severe anaemia in African children.
The SMAART Study (Severe Malaria A Research and Trials consortium) is a prospective observational study that will recruit participants aged 3 months- 15 years for 36 months, admitted to hospital with P. falciparum malaria defined by a positive Paracheck rapid diagnostic test, history of fever or hypothermia and axillary temperature >37.5°C or <36°C.
The primary aim is to characterise the contemporary epidemiology (including features at presentation, diagnostic and treatment pathway) of severe malaria presenting to hospital for admission in children in Africa.
H-PRIME (Hydroxyurea-Pragmatic Reduction In Mortality and Economic burden).
The Trial targets to recruit children diagnosed or suspected to have Sickle Cell Disease aged 1 to 10 years, a laboratory test to confirmed the diagnosis of SCD is mandetory prior to entry.
The trial will have 3 intervention strategies aimed at reducing mortality and morbidity in children with SCD. This include:
R3: antimicrobial prophylaxis with daily co-trimoxazole (CTX) throughout childhood/adolescence vs SOC (twice-daily penicillin V until the age of 5 years).
The results of the Trial will help better up the management of SCD, a growing burden in low developed countries where intensive tests for the management of SCD patients who are on Hydroxyurea are not routinely perform. The data collected shall be kept confidential in line with ICH-GCP guidelines.
2021 Transfusion management of severe anaemia in African children: a consensus algorithm. Maitland K, Kiguli S, Olupot-Olupot P, Opoka RO, Chimalizeni Y, Alaroker F, Uyoga S, Kyeyune- Byabazaire D, M'baya B, Bates I, Williams TN, Munube D, Mbanya D, Molyneux EM, South A, Walker AS, Gibb DM, George EC; TRACT Stakeholders meeting group. Br J Haematol. 2021 May 6. doi: 10.1111/bjh.17429. Online ahead of print. PMID: 33955552
2021 Randomized controlled trial of oxygen therapy and high-flow nasal therapy in African children with pneumonia. Maitland K, Kiguli S, Olupot-Olupot P, Hamaluba M, Thomas K, Alaroker F, Opoka RO, Tagoola A, Bandika V, Mpoya A, Mnjella H, Nabawanuka E, Okiror W, Nakuya M, Aromut D, Engoru C, Oguda E, Williams TN, Fraser JF, Harrison DA, Rowan K; COAST trial group. Intensive Care Med. 2021 May 5. doi: 10.1007/s00134-021-06385-3. Online ahead of print.PMID: 33954839